ABT-894

Results from Phase II study with new ADHD drug

By |2016-10-05T06:46:13-04:00June 20th, 2008|Categories: ADHD, Medication, Research|Tags: , , , , , , , , , |

ABT-894 is a drug that is currently undergoing clinical trials for possible approval by the FDA for the treatment of adult ADHD.  Drugs have to undergo specific study phases and must demonstrate safety and efficacy before they are approved by the FDA.  ABT-894 is a neuronal nictotinic receptor (NNR) modulator.  NNRs modulate the release of neurotransmitters such as acetylcholine and [...]

Comments Off on Results from Phase II study with new ADHD drug
Go to Top